Point-of-care testing for prostate cancer diagnosis
Poster May 06, 2009
This presentation describes the potential of using a new fully automated QCM biosensor and a commercial SPR biosensor for the detection of PSA, a biomarker for prostate cancer. Initially a new buffer was formulated to eliminate 98% of the non-specific human serum protein binding to the sensors. Obtained results indicate that both instruments can be used for the fast and easy detection of PSA (0.29-150 ng/ml) in serum.
The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of phase I (cytochrome P450s), phase II metabolizing enzymes and transporter genes in response to xenobiotics, including prescription drugs.READ MORE